Trichomycosis Market Size, Share, and Industry Analysis, By Type (Trichomycosis Axillaris and Trichomycosis Pubis), By Treatment (Antibacterial {Erythromycin/Clindamycin, Benzoyl peroxide, and Fusidic acid}, and Anti-fungal), By Route of Administration (Oral and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast till 2032

Trichomycosis is a superficial bacterial infection that can develop in areas such as the underarm and the pubic hair. When this bacterial infection occurs in the underarms, it is called trichomycosis axillaris, and trichomycosis pubis when it develops in the pubic hair. Trichomycosis can be diagnosed with Wood's lamp examination test and microscopy. This medical condition is usually treated with antibiotics and anti-fungal drugs.

The expansion of the trichomycosis market is driven by various factors. These encompasses the escalating prevalence of trichomycosis attributed to inadequate hygiene habits coupled with the growing awareness regarding this condition among healthcare providers and individuals. Moreover, the market growth is driven by increasing regulatory approvals for drugs used in the treatment of trichomycosis.

• For instance, in February 2021, Glenmark Pharmaceuticals Limited declared that it had received approval from the U.S. FDA for Clindamycin Phosphate Gel USP. This product is a generic version of Cleocin T 1 Gel developed by Pharmacia & Upjohn. Clindamycin is used to treat trichomycosis by healthcare providers.

Furthermore, several key market players are focusing on the development and launch of topical products used for the treatment of skin-related diseases including trichomycosis.

• For example, in December 2021, Teva Pharmaceutical Industries Ltd. introduced a generic of Epiduo1 Forte Gel (adapalene and benzoyl peroxide gel) in the U.S. market.

The onset of the COVID-19 infection affected the global trichomycosis market in 2020 mainly due to disruptions in dermatology services. In the years leading up to the COVID-19 pandemic, there was a consistent rise in the number of diagnosed skin infections worldwide, exacerbating the burden on the already resource-limited healthcare systems.

• For instance, as per data provided by the LiVDerm in 2024, in the U.S., nearly 14.0 million people per annum were projected to be affected by bacterial and fungal skin conditions.

Moreover, there was traction in industry efforts to improve the understanding and management of skin infections. However, issues such as the COVID-19 pandemic became a significant challenge. However, the increased significance of reducing the spread of skin infections can be attributed to increased attention to personal hygiene during the COVID-19 pandemic.

Key Insights

The report covers the following key insights:

• New Product Launches, By Key Players


• Key Industry Developments - Mergers, Acquisitions, and Partnerships


• Epidemiology of Trichomycosis


• Impact of COVID-19 on the Global Trichomycosis Market

Segmentation

Analysis by Route of Administration

Based on the route of administration, the market can be segmented into oral and topical.

The topical segment is anticipated to exhibit significant growth in the market during the forecast period. The topical solutions are available in the form of gel, cream, lotion, and ointments. The growth of the segment is mainly due to the increasing product launches for topical formulations used in the treatment of trichomycosis along with the easy availability of topical solutions through various distribution channels.

• For instance, in September 2020, Cipla announced the launch of Clocip, which is used to treat skin infections including trichomycosis. This drug is available in the form of dusting powder and cream.

Moreover, the oral segment is anticipated to grow at a considerable CAGR during the forecast period. When topical antibiotics are not working efficiently to treat skin infections, then doctors prescribe oral tablets and pills for the treatment of trichomycosis. The growth of this segment is mainly driven by increasing regulatory approvals for oral antibiotics used in the treatment of trichomycosis.

• For instance, in March 2023, Zydus Lifesciences announced that it had received the U.S. FDA approval for erythromycin tablets. The tablets are indicated for preventing and treating infections across various bodily systems, such as respiratory tract infections, skin infections, legionnaire's disease, diphtheria, acute pelvic inflammatory disease, pertussis, and syphilis.

Regional Analysis

Geographically, the trichomycosis market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for a significant market share in 2023 and is expected to maintain its position over the forecast period. The region's highest growth is owing to the presence of advanced healthcare infrastructure and proactive efforts by healthcare organizations to raise awareness about bacterial infections. In addition, increasing incidences of trichomycosis ultimately increase the demand for antibiotics in the North America region, which is one of the factors boosting the market growth.

• For example, as per data provided by the Dermatology Advisor in December 2019, a research study on trichomycosis axillaris (bacterial infection in underarms) was conducted in the U.S. by several scientists. After the completion of the study, researchers estimated that the incidence of the condition was about 23% after investigating 100 consecutive patients in the U.S.

Furthermore, some key market players are focused on obtaining marketing authorizations that will enable them to produce efficient medicines for the treatment of trichomycosis. This is one of the factors that has contributed to regional growth in the trichomycosis market.

Key Players Covered

The report includes the profiles of key players such as Glenmark Pharmaceuticals Limited, Solaris Pharma Corporation, Galderma, and Bausch Health Companies Inc.

Key Industry Developments

• In October 2023, Bausch Health Companies Inc. announced that the U.S. FDA approved the New Drug Application for CABTREOTM (clindamycin phosphate, adapalene, and benzoyl peroxide) Topical Gel for the treatment of bacterial infection on the skin.

• In May 2022, Bayer announced the relaunch of the novel and improved range of Canesten, their anti-fungal treatment solution in Indian market. This product is available in the form of cream and powder to treat skin infections.

In August 2021, Solaris Pharma Corporation announced that they have received an abbreviated new drug application approval from the U.S. FDA for the first generic version of Clindagel (clindamycin phosphate EQ 1%).